Segment Reporting

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Segment Reporting Disclosure

Segment Reporting

The Company has one reportable segment. The Company’s chief operating decision maker is the Chief Executive Officer and President. The accounting policies of the single segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker assesses performance for the single segment and decides how to allocate resources based on net income (loss) that also is reported on the condensed consolidated statements of operations and comprehensive income (loss) as consolidated net income (loss). The chief operating decision maker uses net income (loss) to monitor budget versus actual results and to evaluate the overall cash burn of the business.

	Three Months Ended March 31,
	2026		2025
	(in thousands)
Revenue	$	179,126	$	1,764
Less:
Imdusiran clinical development expense	891		2,171
AB-101-001 clinical development expense	526		1,899
Other research and development expense	2,703		4,889
General and administrative expense	5,889		5,832
Restructuring expense	—		12,373
Other segment expense (1)	237		323
Add:
Interest income	815		1,197
Segment net income (loss)	$	169,695	$	(24,526)
Adjustments and reconciling items	—		—
Consolidated net income (loss)	$	169,695	$	(24,526)

(1) Other segment expense includes the change in the fair value of contingent consideration, non-cash interest expenses and foreign currency exchange gains and losses.